Press

Origin Therapeutics’ Portfolio Company, Xpira Pharmaceuticals, Receives FDA Approval For Psilocybin Trial IND Application

Sep 22 • 2 min read

Origin Therapeutics Holdings Inc. (CSE: ORIG), an actively managed, psychedelics industry-focused investment issuer, is pleased to announce that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the United States Food and Drug Administration for its first Investigational New Drug (“IND”) application. Xpira Pharmaceuticals is a leader in the development of psychedelic medicines for…

Nirvana Life Sciences Inc. Deuterates 7-Hydroxymitragynine to Create D7-h, an Analogue that May Improve Research and Formulations using Kratom Derivatives

Sep 22 • 5 min read

Nirvana Life Sciences Inc. (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to report filing of a patent for D7-h. Nirvana Life Sciences Inc. is pleased to announce it has recently filed a patent for the deuterated form…

CaaMTech Creates Two New Prodrugs of 4-HO-DiPT

Sep 22 • 2 min read

CaaMTech scientists, in collaboration with the Manke Lab at UMass Dartmouth, recently reported their synthesis and structural characterization of two novel prodrugs of 4-HO-DiPT. The scientists published their research in a paper titled, “The methanol and ethanol solvates of 4-glutarato-N,N-diisopropyltryptamine” in the journal Acta Crystallographica. These are the first crystal structures reported for any 4-substituted DiPT compound,…

Ketamine Wellness Centers (KWC) Partners with Veterans Administration Community Care Network (VA-CCN) To Expand SPRAVATO® Coverage

Sep 22 • 3 min read

Ketamine Wellness Centers (KWC), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings Corp (CSE: DELC | OTCQB: DELCF | FRA: 6X0), has expanded its partnership with the Veterans Administration Community Care Network (VA-CCN) to cover SPRAVATO® treatments at select clinics. The partnership will allow VA-CCN patients experiencing treatment-resistant depression (TRD) to access…

Psyence Group Completes Export of Psilocybin Mushrooms to Canada

Sep 22 • 3 min read

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) has successfully exported psilocybin mushrooms to Psilo Scientific Ltd. in Canada. Psilo Scientific, a wholly owned subsidiary of Filament Health Corp., is an exclusively natural psychedelic drug discovery and extraction company. Psyence received a Health Canada import permit obtained by Psilo Scientific in March 2022. The psilocybin…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441